AnalystsSalim Syed
Salim Syed's Stock Forecasts

Analyst Ranking
Bottom 8%
#5109 out of 5510 analysts
Average Return
-2.18%
Win Rate
44%37 out of 84
Risk vs Reward
Poor
Good

Salim Syed's 5 best and worst ratings

Name / TickerGain/LossEntry PriceExit PricePeriodRating
Nkarta IncNKTX
+149.75%$1.99$4.97
2023-08-14 -
2024-08-13
Strong Buy
Bridgebio Pharma IncBBIO
+149.26%$11.47$28.59
2022-08-24 -
2023-08-23
Strong Buy
Cytokinetics IncCYTK
+145.24%$31.32$76.81
2025-05-29 -
2026-05-28
Buy
Bridgebio Pharma IncBBIO
+105.55%$13.52$27.79
2023-05-08 -
2024-05-07
Strong Buy
Bridgebio Pharma IncBBIO
+89.59%$35.17$66.68
2020-02-19 -
2021-02-19
Strong Buy

Salim Syed's Stock Coverage

Name / TickerNo. RatingsRatingPrice TargetUpside/DownsideActionDate
Bridgebio Pharma IncBBIO
11Buy$110.00+51.85%Maintains
14 days ago
Assembly Biosciences IncASMB
4Buy$45.00+51.01%Maintains
14 days ago
Amgen IncAMGN
8Hold$352.00-6.72%Maintains
a month ago
Enliven Therapeutics IncELVN
4Buy$73.00+34.39%Maintains
a month ago
Wave Life Sciences IncWVE
7Buy$23.00+401.09%Maintains
a month ago
Incyte CorpINCY
2Buy$137.00+12.79%Maintains
a month ago
Biogen IncBIIB
16Buy$241.00+10.98%Maintains
a month ago
Cytokinetics IncCYTK
8Buy$118.00+59.96%Maintains
3 months ago
Century Therapeutics IncIPSC
1Buy$8.00+312.37%Initiates Coverage On
4 months ago
Sutro Biopharma IncSTRO
1Buy$50.00+196.56%Initiates Coverage On
5 months ago
Autolus Therapeutics PLCAUTL
1Buy$10.00+431.91%Maintains
5 months ago
Syndax Pharmaceuticals IncSNDX
1Buy$43.00+136.52%Maintains
5 months ago
Nkarta IncNKTX
9Buy$12.00+312.37%Maintains
5 months ago
Maze Therapeutics IncMAZE
1Buy$97.00+294.31%Initiates Coverage On
6 months ago
Gilead Sciences IncGILD
6Buy$117.00N/AMaintains
a year ago
Vaxcyte IncPCVX
3Buy$163.00N/AMaintains
2 years ago
Atara Biotherapeutics IncATRA
4Buy$18.00N/AUpgrades
2 years ago
Crispr Therapeutics AgCRSP
3Strong Buy$99.00N/AMaintains
3 years ago
Unity Biotechnology IncUNBX
5Strong Buy$6.00N/AMaintains
3 years ago
Coherus Oncology IncCHRS
3Strong Buy$21.00N/AMaintains
4 years ago
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.